ANTICUERPOS Y FRAGMENTO FV QUE RECONOCEN EL ANTIGENO IOR C2

Anticuerpo recombinante y fragmento de tipo Fv de cadena sencilla derivados del anticuerpo monoclonal murino IOR C5 producido por el hibridoma con número de depósito ECCC 97061101, donde dicho anticuerpo recombinante contiene las Regiones Determinantes de la Complementariedad (CDRs) del anticuerpo I...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MATEO DE ACOSTA DEL RIO CRISTINA MARIA, MORALES MORALES ALEJO, DUENAS PORTO MARTA, PEREZ RODRIGUEZ ROLANDO, AYALA AVILA MARTA, BELL GARCIA HANSSEL, RENGIFO CALZADO ENRIQUE, GAVILONDO COWLEY JORGE VICTOR, ROQUE NAVARRO LOURDES TATIANA, ESCOBAR NORMANDO IZNAGA, RAMOS ZUZARTE MAYRA
Format:	Patent
Sprache:	spa
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Anticuerpo recombinante y fragmento de tipo Fv de cadena sencilla derivados del anticuerpo monoclonal murino IOR C5 producido por el hibridoma con número de depósito ECCC 97061101, donde dicho anticuerpo recombinante contiene las Regiones Determinantes de la Complementariedad (CDRs) del anticuerpo IOR C5 y regiones constantes humanas en las cadenas pesadas y ligeras.Composición farmacéutica para el tratamiento de tumores malignos de colon y recto, sus metástasis y recidivas que contiene uno de los anticuerpos recombinantes de las reivindicaciones de la 1 a la 5, y un excipiente apropiado para su aplicación. The invention relates to the obtention of novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101 according to the Budapest Treaty. Said recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.